A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05884242
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
- Conditions
- Depressive Disorder, Major
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 500
- Registration Number
- NCT05841030
- Locations
- π¦π·
CEN Consultorios Especializados en Neurociencias, Cordoba, Argentina
π¦π·Instituto Medico DAMIC, Cordoba, Argentina
π¦π·Centro Medico Luquez, Cordoba, Argentina
A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT05827874
- Locations
- π©πͺ
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Neoplasms
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 185
- Registration Number
- NCT05818683
- Locations
- π¦πΊ
Icon Cancer Centre Kurralta Park, Kurralta Park, Australia
π¦πΊPeter MacCallum Cancer Centre, Melbourne, Australia
πΊπΈPerlmutter Cancer Center at NYU Langone Brooklyn, Brooklyn, New York, United States
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- Conditions
- Geographic Atrophy
- Interventions
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 305
- Registration Number
- NCT05811351
- Locations
- π©πͺ
Medizinische Hochschule Hannover, Hannover, Germany
π©πͺUniversitatsklinikum Schleswig Holstein Kiel, Kiel, Germany
π©πͺUniversitaetsklinikum Leipzig, Leipzig, Germany
A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT05784129
- Locations
- πΊπΈ
Gastro Health Ohio, Cincinnati, Ohio, United States
πΊπΈSouthern Star Research Institute, LLC, San Antonio, Texas, United States
πΊπΈMedical Associates Research Group, Inc., San Diego, California, United States
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
- Conditions
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05784441
- Locations
- πΊπΈ
University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈUniversity of Iowa Hospital, Iowa City, Iowa, United States
π¦πΊMonash Medical Centre, Clayton, Australia
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20296
- Registration Number
- NCT05757869
- Locations
- π§π¬
UMHAT 'Heart and Brain Center for Excellence', Pleven, Bulgaria
π§π¬UMHAT 'Sv. Georgi' EAD, Plovdiv, Bulgaria
π§π¬Medical Center- Prolet Ltd, Ruse, Bulgaria
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05757973
- Locations
- π¬π§
DUMMY, Dummy, United Kingdom
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16000
- Registration Number
- NCT05754957
- Locations
- π―π΅
Fukui Prefectural Hospital, Fukui-shi, Japan
π―π΅Fukuoka Wajiro Hospital, Fukuoka-shi, Japan
π·πΈHealth Center Zajecar, Zajecar, Serbia